Application of exhaled nitric oxide (FeNO) in pediatric asthma
| Autor: | Diego Peroni, Maria Di Cicco, Vincenzo Ragazzo, Pasquale Comberiati |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
medicine.medical_specialty Immunology Inhaled corticosteroids Omalizumab Nitric Oxide Type-2 inflammation children immune system diseases Immunology and Allergy Medicine Humans FeNO Intensive care medicine Child Pediatric asthma Asthma Inflammation Moderately good business.industry respiratory system medicine.disease allergy Dupilumab respiratory tract diseases biologicals Breath Tests Exhalation Child Preschool Exhaled nitric oxide Biomarker (medicine) allergy asthma biologicals children FeNO Type-2 inflammation business Biomarkers medicine.drug |
| Zdroj: | Current opinion in allergy and clinical immunology. 21(2) |
| ISSN: | 1473-6322 |
| Popis: | PURPOSE OF REVIEW Fractional concentration of Nitric Oxide in the exhaled air (FeNO) is a moderately good biomarker of type-2 airway inflammation, and its measurement is feasible also in children. The available evidence is still not enough to support the routine use of FeNO to diagnose or manage asthma in every patient in clinical practice. However, its role in identifying asthma with eosinophilic inflammation is of particular interest in the management of severe asthma. RECENT FINDINGS In healthy subjects, FeNO levels increase with age and height, particularly in males, and are also influenced by ethnicity. FeNO measurement can support asthma diagnosis and help in predicting asthma development later in life in young children with recurrent wheezing. FeNO-guided asthma management is effective in reducing asthma exacerbations but may result in a higher daily dose of inhaled corticosteroids. FeNO can also be used as a marker to evaluate adherence to asthma treatment and predict response to different biologicals, especially Omalizumab and Dupilumab. SUMMARY This review outlines recent data on the application of FeNO in childhood-onset asthma diagnosis and management, as well as in phenotyping subjects with severe asthma who may benefit from monoclonal antibodies administration. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|